{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:21:59Z","timestamp":1780514519665,"version":"3.54.1"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>\n                    Alport syndrome (AS) and immunoglobulin A (IgA) nephropathy (IgAN) are distinct renal disorders characterized by hematuria and proteinuria. AS is a rare hereditary condition caused by mutations in genes encoding collagen IV\n                    <jats:italic>\u03b1<\/jats:italic>\n                    -chains, leading to abnormalities of the glomerular basement membrane. However, IgAN is an autoimmune disorder characterized by glycosylation defects in IgA1, leading to dysfunction of glomerular filtration. Approximately 15% of IgAN cases exhibit familial clustering, and some may harbor gene mutations associated with AS. A 29-year-old woman with no family history of nephropathy presented with hematuria and proteinuria. The renal biopsy revealed foamy interstitial cells. Electron microscopy indicated a torn basement membrane, indicating a diagnosis of concurrent AS and mild mesangial proliferative IgAN. Genetic testing confirmed a mutation consistent with X-linked AS. Moreover, she exhibited high-frequency hearing loss in her left ear. Initial treatment included angiotensin receptor blockers and sodium-glucose co-transporter-2 inhibitors. Corticosteroids and mycophenolate mofetil were introduced prior to genetic testing, although their efficacy was limited. Despite the co-occurrence of multiple nephropathies, this case suggests the usefulness of renal biopsy and genetic testing for accurately diagnosing kidney disease, which can help initiate appropriate treatments early. The treatment regimen did not provide significant benefits in this patient with concurrent AS and IgAN. This emphasizes the need for targeted diagnostics and personalized therapeutic approaches.\n                  <\/jats:p>","DOI":"10.3389\/fmed.2026.1739845","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T05:18:55Z","timestamp":1771219135000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Alport syndrome complicated with IgA nephropathy: a case report"],"prefix":"10.3389","volume":"13","author":[{"given":"Jing","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Nephropathy Rheumatology and Immunology, The People\u2019s Hospital of QianNan","place":["Duyun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Guizhou Provincial People\u2019s Hospital","place":["Guiyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1681\/ASN.2020071065","article-title":"Prevalence estimates of predicted pathogenic COL4A3-COL4A5 variants in a population sequencing database and their implications for Alport syndrome","volume":"32","author":"Gibson","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000520039","article-title":"IgA nephropathy: a Chinese perspective","volume":"2","author":"Zhang","year":"2022","journal-title":"Glomerular Dis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1186\/s12882-021-02567-9","article-title":"Tale of two nephropathies; co-occurring Alport syndrome and IgA nephropathy, a case report","volume":"22","author":"Bhattacharyya","year":"2021","journal-title":"BMC Nephrol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12882-023-03165-7","article-title":"Alport syndrome misdiagnosed with IgA nephropathy from familial history: a case report and brief review","volume":"24","author":"Rahimzadeh","year":"2023","journal-title":"BMC Nephrol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ekir.2020.10.015","article-title":"Increased lifetime risk of ESRD in familial IgA nephropathy","volume":"6","author":"Shi","year":"2021","journal-title":"Kidney International Reports"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"567","DOI":"10.16121\/j.cnki.cn45-1347\/r.2023.06.12","article-title":"Analysis of a northern Han Chinese family with familial IgA nephropathy and pathogenic gene diagnosis","volume":"18","author":"Yang","year":"2023","journal-title":"Int Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.gene.2015.06.041","article-title":"Novel genes and variants associated with IgA nephropathy by co-segregating with the disease phenotypes in 10 IgAN families","volume":"571","author":"Liu","year":"2015","journal-title":"Gene"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1159\/000503564","article-title":"An exome sequencing study of 10 families with IgA nephropathy","volume":"144","author":"Stapleton","year":"2020","journal-title":"Nephron"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"5522","DOI":"10.3390\/ijms24065522","article-title":"Current and future therapeutical options in Alport syndrome","volume":"24","author":"Reiterova","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1159\/000492438","article-title":"Diagnosing Alport syndrome: lessons from the Pediatric Ward","volume":"140","author":"Vos","year":"2018","journal-title":"Nephron"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/j.ekir.2021.02.022","article-title":"Rare collagenous heterozygote variants in children with IgA nephropathy","volume":"6","author":"Cambier","year":"2021","journal-title":"Kidney Int Rep"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.3390\/cells13131157","article-title":"Role of the innate immune response in glomerular disease pathogenesis: focus on podocytes","volume":"13","author":"Issa","year":"2024","journal-title":"Cells"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/ki.2010.373","article-title":"Bacterial CpG-DNA accelerates Alport glomerulosclerosis by inducing an M1 macrophage phenotype and tumor necrosis factor-\u03b1-mediated podocyte loss","volume":"79","author":"Ryu","year":"2011","journal-title":"Kidney Int"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.kint.2017.12.018","article-title":"<article-title update=\"added\">Alport syndrome: a unified classification of genetic disorders of collagen IV \u03b1345: a position paper of the Alport syndrome classification working group","volume":"93","author":"Kashtan","year":"2018","journal-title":"Kidney Int"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/path.6087","article-title":"Dual inhibition of the endothelin and angiotensin receptor ameliorates renal and inner ear pathologies in Alport mice","volume":"260","author":"Cosgrove","year":"2023","journal-title":"J Pathol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e2254054","DOI":"10.1001\/jamanetworkopen.2022.54054","article-title":"Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial","volume":"6","author":"Hou","year":"2023","journal-title":"JAMA Netw Open"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s11255-017-1574-2","article-title":"Hydroxychloroquine alleviates persistent proteinuria in IgA nephropathy","volume":"49","author":"Gao","year":"2017","journal-title":"Int Urol Nephrol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e16256","DOI":"10.1097\/md.0000000000016256","article-title":"Fabry disease and immunoglobulin a nephropathy presenting with Alport syndrome-like findings: a case report","volume":"98","author":"Ren","year":"2019","journal-title":"Medicine (Baltimore)"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1739845\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T05:18:56Z","timestamp":1771219136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1739845\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":19,"alternative-id":["10.3389\/fmed.2026.1739845"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1739845","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"article-number":"1739845"}}